Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Cash (2019 - 2025)

Historic Change in Cash for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $106.3 million.

  • Avidity Biosciences' Change in Cash rose 15168.76% to $106.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.0 million, marking a year-over-year decrease of 10697.68%. This contributed to the annual value of $37.3 million for FY2024, which is 12401.37% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Change in Cash is $106.3 million, which was up 15168.76% from -$10.3 million recorded in Q2 2025.
  • Avidity Biosciences' Change in Cash's 5-year high stood at $286.3 million during Q1 2024, with a 5-year trough of -$221.7 million in Q1 2023.
  • For the 5-year period, Avidity Biosciences' Change in Cash averaged around $1.6 million, with its median value being -$10.3 million (2025).
  • As far as peak fluctuations go, Avidity Biosciences' Change in Cash surged by 128179.41% in 2021, and later tumbled by 79621.08% in 2022.
  • Quarter analysis of 5 years shows Avidity Biosciences' Change in Cash stood at -$89.6 million in 2021, then surged by 319.61% to $196.7 million in 2022, then crashed by 49.45% to $99.4 million in 2023, then plummeted by 251.18% to -$150.3 million in 2024, then soared by 170.68% to $106.3 million in 2025.
  • Its last three reported values are $106.3 million in Q3 2025, -$10.3 million for Q2 2025, and $34.3 million during Q1 2025.